Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2020-04-15 Major Shareholding Noti…
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change in substantial holding 2 pages 79.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and shareholdings of a substantial holder, including dates, number of shares, and nature of transactions. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2020-04-15 English
Becoming a substantial holder 51 pages 259.4KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references 'Corporations Law Section 671B' which pertains to the notice of an initial substantial holder. It details the substantial shareholding of Bank of America Corporation and its related bodies corporate in Opthea Ltd, including voting power, relevant interests, registered holders, and changes in securities holdings. The document is a formal notification of a substantial shareholding position, which aligns with the definition of a Major Shareholding Notification. There is no financial performance data, management discussion, or other report content. The document length is substantial and contains detailed shareholding information, not a brief announcement or certification. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2020-03-30 English
Opthea Completes Patient Dosing in Phase 2a DME Trial 3 pages 170.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX and media release dated 30 March 2020 from Opthea Limited. It announces the completion of patient dosing in a Phase 2a clinical trial and provides a business update related to COVID-19. The content focuses on clinical trial progress, business strategy, and financial runway but does not contain detailed financial statements or comprehensive financial performance data. It is a corporate update and operational progress announcement rather than a formal financial report or earnings release. The document length is 8806 characters, which is moderate, but the content is clearly an announcement rather than a full report. There is no indication of quarterly or annual financial results, no detailed financial tables, and no regulatory form references. Therefore, the document best fits the category of a Capital/Financing Update (CAP) as it includes information about financing status and business updates relevant to investors.
2020-03-29 English
Ceasing to be a substantial holder from MS 16 pages 922.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605 Corporations Act 2001 Section 671B' and is a 'Notice of ceasing to be a substantial holder' for the company Opthea Limited. It details changes in relevant interests of a substantial holder, Morgan Stanley and its subsidiaries, including dates, nature of changes, and number of securities affected. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category 'Major Shareholding Notification' (MRQ). The document is lengthy and contains detailed transaction data, not just an announcement or a brief note, confirming it is the actual notification. Therefore, the correct classification is MRQ with high confidence.
2020-03-25 English
Ceasing to be a substantial holder from MUFG 12 pages 386.4KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and is a 'Notice of ceasing to be a substantial holder' under the Corporations Act 2001 Section 671B. It details changes in relevant interests of a substantial holder, Mitsubishi UFJ Financial Group, Inc., including purchases and sales of securities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management information, but a regulatory notice about shareholding changes.
2020-03-25 English
Becoming a substantial holder from MS 84 pages 5.0MB
Regulatory Filings
2020-03-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.